Point72 Hong Kong’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Point72 Hong Kong’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-355	Closed	-$1K	–	1853
2022 Q3	$1K	Sell	355 -1,835	-84%	-$6.5K	﹤0.01%	1870
2022 Q2	$7K	Buy	+2,190	New	+$10.7K	﹤0.01%	1716
2021 Q3	–	Sell	-4,606	Closed	-$31K	–	2572
2021 Q2	$31K	Buy	4,606 +2,597	+129%	+$21.6K	﹤0.01%	1566
2021 Q1	$21K	Buy	+2,009	New	+$22K	﹤0.01%	1468
2020 Q4	–	Sell	-1,642	Closed	-$13K	–	2125
2020 Q3	$13K	Buy	+1,642	New	+$10.2K	﹤0.01%	954
2020 Q1	–	Sell	-869	Closed	-$8K	–	1472
2019 Q4	$8K	Buy	+869	New	+$4.7K	﹤0.01%	1008
2018 Q2	–	Sell	-33	Closed	-$1K	–	1267
2018 Q1	$1K	Buy	+33	New	+$732	﹤0.01%	858

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Point72 Hong Kong's JNCE Position: Q4 2022 in Review

Point72 Hong Kong sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 355 shares — an estimated $1K sold.

Point72 Hong Kong first reported a position in JNCE in Q1 2018 and held it in 7 quarters. The position peaked at $31K in Q2 2021. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

Point72 Hong Kong reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Point72 Hong Kong sold 355 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
Point72 Hong Kong first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 7 quarters.
Point72 Hong Kong's Jounce Therapeutics, Inc. Common Stock position peaked at $31K in Q2 2021.
85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.